Thermal ablation with magnetic resonance–guided focused ultrasound surgery (MRgFUS) is a noninvasive technique for treating fibroids and cancer. New research from UC Davis shows that combining the technique with chemotherapy can allow complete destruction of tumors in mice.
MRgFUS combines an ultrasound beam that heats and destroys tissue with a magnetic resonance imaging to guide the beam and monitor the effects of treatment. The effectiveness of the treatment can be limited by the need to spare normal tissue or critical structures on the tumor margins, as well as the need to eliminate micrometastases.
In a new paper in The Journal of Clinical Investigation, Katherine W. Ferrara, distinguished professor of biomedical engineering at UC Davis, and colleagues report on a strategy that can destroy an entire tumor without thermal destruction of the tumor margin. Her group demonstrated a dramatic increase in the concentration of anti-cancer chemotherapy within several types of MRgFUS thermal ablation-treated tumors.
“MRgFUS is already FDA approved for the treatment of uterine fibroids and palliation of bone metastases. We hope to expand the indication for MRgFUS by supplementing it with chemotherapy,” said first author Andrew Wong, a graduate student with the UC Davis Physician Scientist Training Program.
Ferrara’s previous research has shown that ultrasound-induced mild hyperthermia can enhance the accumulation of tiny nanoparticles carrying anti-cancer drugs, but the accumulation is dependent on the type of tumor. Her group hypothesized that combining thermal ablation and chemotherapy could improve efficacy across multiple types of tumors.
The team used a variety of techniques including combined positron emission tomography/computed tomography (PET-CT), magnetic resonance imaging, autoradiography, and fluorescence imaging to track nanoparticles loaded with the chemotherapy drug doxorubicin in a mouse model of breast cancer.
They found that as the ultrasound damaged the tumor and induced a local immune response, nanoparticles accumulated in the tumor and the local drug concentration increased 50-fold. The high drug concentrations continued over several weeks, increasing total exposure of the tumor to the drug.
Ferrara’s research team found that the enhanced drug accumulation induced by MRgFUS resulted in improved survival and a consistent cure in their preclinical model of breast cancer, even when part of the tumor was left intact.
They also demonstrated that an effective cure could be achieved with a carefully designed protocol involving heat-activated nanoparticles, which, when gently heated by ultrasound, release their chemotherapeutic payload in the vasculature surrounding the tumor.
The Latest on: MRgFUS
via Google News
The Latest on: MRgFUS
- MR-Guided Focused Ultrasound for the Novel and Innovative Management of Osteoarthritic Knee Painon August 1, 2020 at 5:00 pm
This is the first report of clinical application of MRgFUS for knee OA. Real-time monitoring of the sonication area and temperature elevation enabled performance of safe and accurate treatment.
- FDA Clears ExAblate Fertility Enhancement Study in Women With Uterine Fibroidson July 19, 2020 at 12:47 am
Study Will Compare Birth Rates of Women who Underwent Non-Invasive MRgFUS to Those who had Invasive Fibroid Surgery InSightec Ltd. announced today that the U.S. Food and Drug Administration (FDA) ...
- MR-Guided Focused Ultrasound for the Novel and Innovative Management of Osteoarthritic Knee Painon July 10, 2020 at 5:00 pm
Two patients (Case 2 and 3) underwent total knee arthroplasty one month after MRgFUS treatment. One of the non-responders (Case 8) dropped out and switched to opioid therapy one month after MRgFUS ...
- Nanox Signs Agreement With Promedica Bioelectronics for the Deployment of 500 Nanox.ARC Units in Italyon June 8, 2020 at 3:55 pm
Since 2008 Exclusive Distributor at National Level for MRgFUS products developed by Insightec Ltd. Promedica achieve the largest Installed Base of MRgFUS equipments in the World.For more ...
- Nanox Signs Agreement With Promedica Bioelectronics for the Deployment of 500 Nanox.ARC Units in Italyon June 8, 2020 at 5:53 am
Following COVID 19 Pandemic, Nanox and Promedica Bioelectronics aim to provide significantly higher medical imaging availability to both public and private Italian medical NANO-X IMAGING LTD ...
- Missing Treatment Optionon September 6, 2019 at 7:52 pm
The authors discuss numerous treatments of fibroids (1), including MR-guided focused ultrasound surgery (MRgFUS/MRgHIFU). However, no reference is made to the option of ultrasound-guided high ...
- Stanford Essential Tremor Programon June 1, 2018 at 11:12 am
MR Guided Focused Ultrasound (MRgFUS) precisely targets high intensity ultrasound waves through the skull to a nucleus in the thalamus, an area of the brain responsible for causing tremors. MRgFUS ...
- Insightec: The Taiwanese Food and Drug Administration (TFDA) Approved Exablate Neuro for the Treatment of Essential Tremoron November 28, 2017 at 6:11 pm
INSIGHTEC, the leader in MR-guided Focused Ultrasound (MRgFUS) therapy, announced today that the Taiwanese Food and Drug Administration (TFDA) has approved its Exablate Neuro system for the treatment ...
- The Richard M. Lucas Center for Imagingon February 26, 2017 at 4:29 pm
Investigators throughout the world are currently applying MR-guided focused ultrasound (MRgFUS) for non-invasive treatments of a variety of diseases and disorders. Typically, focused ultrasound uses a ...
- In Replyon April 30, 2015 at 3:35 pm
The factors determining its suitability for the treatment of fibroids are almost identical with those for MR-guided focused ultrasound surgery (MRgFUS). The success rates and the unincreased ...
via Bing News